Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41598-020-74001-3 http://scihub22266oqcxt.onion/10.1038/s41598-020-74001-3 33033405!7545205!33033405     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Sci+Rep 2020 ; 10 (1): 16826 Nephropedia Template TP {{tp|p=33033405|t=2020. Preemptive interleukin-6 blockade in patients with COVID-19 |pdf=|usr=}}{{33033405}} gab.com Text Preemptive interleukin-6 blockade in patients with COVID-19 JO: Sci Rep http://www.kidney.de/pget.php?&tw=1&pmid=33033405 #FOAvip Excessive interleukin-6 signaling is a key factor contributing to the cytokine release syndrome implicated in clinical manifestations of COVID-19. Preliminary results suggest that tocilizumab, a humanized monoclonal anti-interleukin-6 receptor antibody, may be beneficial in severely ill patients, but no data are available on earlier stages of disease. An anticipated blockade of interleukin-6 might hypothetically prevent the catastrophic consequences of the overt cytokine storm. We evaluated early-given tocilizumab in patients hospitalized with COVID-19, and identified outcome predictors. Consecutive patients with initial Sequential-Organ-Failure-Assessment (SOFA) score < 3 fulfilling pre-defined criteria were treated with tocilizumab. Serial plasma biomarkers and nasopharyngeal swabs were collected. Of 193 patients admitted with COVID-19, 64 met the inclusion criteria. After tocilizumab, 49 (76.6%) had an early favorable response. Adjusted predictors of response were gender, SOFA score, neutrophil/lymphocyte ratio, Charlson comorbidity index and systolic blood pressure. At week-4, 56.1% of responders and 30% of non-responders had cleared the SARS-CoV-2 from nasopharynx. Temporal profiles of interleukin-6, C-reactive protein, neutrophil/lymphocyte ratio, NT-ProBNP, D-dimer, and cardiac-troponin-I differed according to tocilizumab response and discriminated final in-hospital outcome. No deaths or disease recurrences were observed. Preemptive therapy with tocilizumab was safe and associated with favorable outcomes in most patients. Biological and clinical markers predicted outcomes. Twit Text FOAVip Preemptive interleukin-6 blockade in patients with COVID-19 ????Sci Rep http://www.kidney.de/pget.php?&tw=1&pmid=33033405 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33033405 #FOAvip English Wikipedia <ref>{{Cite pmid|33033405}}</ref> Preemptive interleukin-6 blockade in patients with COVID-19 #MMPMID33033405 Guillen L; Padilla S; Fernandez M; Agullo V; Garcia JA; Telenti G; Garcia-Abellan J; Botella A; Gutierrez F; Masia M Sci Rep 2020[Oct]; 10 (1): 16826 PMID33033405show ga Excessive interleukin-6 signaling is a key factor contributing to the cytokine release syndrome implicated in clinical manifestations of COVID-19. Preliminary results suggest that tocilizumab, a humanized monoclonal anti-interleukin-6 receptor antibody, may be beneficial in severely ill patients, but no data are available on earlier stages of disease. An anticipated blockade of interleukin-6 might hypothetically prevent the catastrophic consequences of the overt cytokine storm. We evaluated early-given tocilizumab in patients hospitalized with COVID-19, and identified outcome predictors. Consecutive patients with initial Sequential-Organ-Failure-Assessment (SOFA) score < 3 fulfilling pre-defined criteria were treated with tocilizumab. Serial plasma biomarkers and nasopharyngeal swabs were collected. Of 193 patients admitted with COVID-19, 64 met the inclusion criteria. After tocilizumab, 49 (76.6%) had an early favorable response. Adjusted predictors of response were gender, SOFA score, neutrophil/lymphocyte ratio, Charlson comorbidity index and systolic blood pressure. At week-4, 56.1% of responders and 30% of non-responders had cleared the SARS-CoV-2 from nasopharynx. Temporal profiles of interleukin-6, C-reactive protein, neutrophil/lymphocyte ratio, NT-ProBNP, D-dimer, and cardiac-troponin-I differed according to tocilizumab response and discriminated final in-hospital outcome. No deaths or disease recurrences were observed. Preemptive therapy with tocilizumab was safe and associated with favorable outcomes in most patients. Biological and clinical markers predicted outcomes. |*Betacoronavirus[MESH] |*Organ Dysfunction Scores[MESH] |Aged[MESH] |Aged, 80 and over[MESH] |Antibodies, Monoclonal, Humanized/adverse effects/*pharmacology/*therapeutic use[MESH] |Biomarkers/blood[MESH] |C-Reactive Protein/analysis[MESH] |COVID-19[MESH] |COVID-19 Drug Treatment[MESH] |Coronavirus Infections/*drug therapy/epidemiology/virology[MESH] |Female[MESH] |Follow-Up Studies[MESH] |Humans[MESH] |Interleukin-6/blood[MESH] |Lymphocyte Count[MESH] |Lymphocytes[MESH] |Male[MESH] |Middle Aged[MESH] |Neutrophils[MESH] |Pandemics[MESH] |Pneumonia, Viral/*drug therapy/epidemiology/virology[MESH] |Receptors, Interleukin-6/*antagonists & inhibitors[MESH] |SARS-CoV-2[MESH] |Spain/epidemiology[MESH]Preemptive interleukin-6 blockade in patients with COVID-19 (epmc).pdf DeepDyve Pubget Overpricing